In fact, therapies combining other anticancer agents with recombinant TRAIL have shown in vitro and in vivo improved efficacy for cancer treatment by modulating TRAIL‐resistant mechanisms.23, 24, 25. This evidence concerns the gene TNFSF10 and cancer.